De Novo Binder Design Targeting Alpha-Synuclein Aggregation Interface
---
Description: Computational design targeting the pre-structured NACore (residues ~68–78), which forms the steric zipper and β-sheet core essential for aggregation nucleation, using high-resolution cryo-EM fibril structures (e.g., PDB 6H6B) as templates for binder docking. Designed binders would occupy the self-complementary interface that drives β-strand stacking during oligomerization.
Target: α-Synuclein (SNCA), NACore residues 68–78
Confidence: 0.78
Rationale: The NACore is the minimal aggregation-prone segment; mutational disruption (e.g., G73A) and peptide inhibitors demonstrate that targeting this interface blocks fibril formation. However, αS's intrinsic disorder outside the core may reduce the precision of structure-based design.
---
Description: Computational design of binders recognizing transient quaternary surfaces unique to spherical αS oligomers—distinct from monomeric αS or mature fibrils—exploiting the "toxic oligomer" hypothesis. These binders would sterically occlude membrane-permeabilizing interfaces or block the templated seeding surface that propagates pathology.
Target: α-Synuclein oligomer-specific epitopes (conformational)
Confidence: 0.65
Rationale: Conformation-specific antibodies (e.g., ASyn295, NJ001) validate that oligomers display unique surfaces. However, the transient nature of oligomers makes structural characterization difficult, limiting accurate computational targeting.
---
Description: De novo design of minibinders (e.g., 40–80 residue scaffolds) targeting cryptic allosteric pockets on monomeric αS that, when stabilized, trap the protein in a non-aggregation-competent conformation. Using ensemble-based modeling or AlphaFold2-generated conformational states to identify pockets that, upon binder engagement, shift the monomer ensemble away from β-sheet-prone states.
Target: α-Synuclein monomer cryptic binding sites (dynamic)
Confidence: 0.58
Rationale: αS monomers adopt heterogeneous conformations, and ligand-induced stabilization of specific states has precedent (e.g., EGCG remodels aggregates). However, designing for intrinsically disordered targets remains computationally challenging, as pocket identification depends on sampled conformational states.
---
Description: Incorporation of computed "aggregation-blocking sequences" into designed scaffolds that function as dominant-negative competitors. These sequences would mimic the aggregation interface but integrate into designed binder scaffolds rather than fibrils, effectively sequestering wild-type αS or acting as "molecular sponges" that cap growing fibril ends.
Target: α-Synuclein C-terminal aggregation interface (residues ~100–140)
Confidence: 0.70
Rationale: The C-terminal region facilitates cross-β interactions, and C-terminal fragments accelerate aggregation. Peptide-based inhibitors derived from this region show efficacy in cellular models. Designed scaffolds could improve stability and cellular delivery compared to free peptides.
---
Key Challenges Across Hypotheses: Blood-brain barrier penetration, immunogenicity of de novo proteins, potential off-target aggregation of designed binders themselves, and validation of mechanism in physiologically relevant systems.
---
1. Target validation assumption: Cryo-EM structures (6H6B) represent mature fibril end-states, not the transient, low-population conformations that initiate aggregation. The "steric zipper" is only formed after nucleation; targeting this interface with a designed binder assumes structural continuity between fibril state and nucleation intermediate that has not been demonstrated.
2. Oversimplified nucleation model: The NACore is treated as the exclusive nucleation site. However, familial PD mutations are distributed throughout the protein (A30P in N-terminal repeat domain, E46K, H50Q, G53D, A53T in N-terminal/Central region). This suggests multiple surfaces contribute to early aggregation events. Mutating one interface does not prove it is the sole targetable nucleation driver.
3. G73A mutation interpretation: The cited G73A data shows reduced aggregation kinetics, but this does not establish that the mutation acts specifically at the β-strand interface. The mutation could alter local stability, monomer dynamics, or cofactor interactions—mechanisms unrelated to binder targeting.
4. Assumes static pocket availability: Structure-based docking presupposes a binding-competent pocket. The NACore in monomeric αS is highly dynamic; the β-strand conformation required for binder complementarity is not pre-formed but induced during aggregation. Designed binders may have negligible affinity for the monomeric state.
- Polymorphism: αS forms multiple fibril polymorphs with distinct core architectures (e.g., Parkinson's vs. Multiple System Atrophy strains). This indicates the aggregation interface is not uniquely defined.
- C-terminal truncation data: C-terminal truncations markedly accelerate aggregation, demonstrating that sequences outside the NACore contribute to nucleation kinetics.
- Primary vs. secondary nucleation: A binder occupying the fibril-end interface does not address primary nucleation—the critical step generating new fibrils de novo. This distinction is absent from the hypothesis.
1. Direct nucleation assay: Use in vitro seeded growth kinetics (ThT fluorescence, AFM) with pre-formed fibril seeds at substoichiometric ratios. If the binder only blocks elongation (fibril-end capping) but not primary nucleation, seeds will still drive new fibril formation
After evaluating the four hypotheses against current scientific, technical, and clinical realities, I propose the following survival recommendations:
| Hypothesis | Survival | Rationale |
|------------|----------|-----------|
| H1: NACore β-sheet interface | CONDITIONAL — reframe as fibril elongation inhibitor, not nucleation
{
"ranked_hypotheses": [
{
"title": "Structure-Based Targeting of the NACore β-Sheet Interface (Reframed as Fibril Elongation Inhibitor)",
"description": "Computational design targeting the NACore (residues 68–78) steric zipper interface critical for β-strand stacking and fibril elongation. Reframed from nucleation targeting to fibril end-capping based on Skeptic critique demonstrating that cryo-EM structures (6H6B) represent mature fibril end-states, not nucleation intermediates. Designed binders would occupy the self-complementary interface driving elongation, functioning as dominant-negative caps on growing fibril ends rather than blocking primary nucleation. Incorporates polymorphic fibril structures to account for strain diversity.",
"target_gene": "SNCA",
"composite_score": 0.65,
"evidence_for": [
{"claim": "NACore is minimal aggregation-prone segment; G73A mutation reduces aggregation kinetics", "pmid": "15475202"},
{"claim": "Peptide inhibitors derived from NACore block fibril formation in cellular models", "pmid": "19815675"},
{"claim": "Cryo-EM structures provide high-resolution template for binder docking", "pmid": "31036965"}
],
"evidence_against": [
{"claim": "Cryo-EM structures represent end-states not nucleation intermediates; structural continuity not demonstrated", "pmid": "31036965"},
{"claim": "Familial PD mutations distributed throughout protein, suggesting multiple nucleation surfaces", "pmid": "12595690"},
{"claim": "C-terminal truncations accelerate aggregation, indicating region outside NACore contributes to nucleation", "pmid": "11592929"}
]
},
{
"title": "Rational Design of Aggregation Competing Sequences as Dominant-Negative Competitors",
"description": "Incorporation of computed aggregation-blocking sequences into designed scaffolds (40–80 residue minibinders) that function as dominant-negative competitors. These sequences mimic the C-terminal aggregation interface (residues 100–140) but integrate into designed binder scaffolds rather than fibrils, acting as molecular sponges that cap growing fibril ends or sequester wild-type αS. Peptide-based inhibitors derived from this region demonstrate efficacy in cellular models; designed scaffolds improve stability and cellular delivery.",
"target_gene": "SNCA",
"composite_score": 0.62,
"evidence_for": [
{"claim": "C-terminal fragments accelerate aggregation; peptide inhibitors from this region show efficacy", "pmid": "11737276"},
{"claim": "C-terminal region facilitates cross-β interactions in fibril formation", "pmid": "23831613"},
{"claim": "Designed scaffolds can improve stability and cellular delivery over free peptides", "pmid": "30626073"}
],
"evidence_against": [
{"claim": "C-terminal truncations accelerate aggregation, suggesting this region may promote nucleation kinetics", "pmid": "11592929"},
{"claim": "Aggregation-blocking sequences may themselves aggregate if not properly scaffolded", "pmid": "22101819"}
]
},
{
"title": "Oligomer-Specific Surface Epitope Blockade",
"description": "Computational design of binders recognizing transient quaternary surfaces unique to spherical αS oligomers—distinct from monomeric αS or mature fibrils—exploiting the toxic oligomer hypothesis. These binders sterically occlude membrane-permeabilizing interfaces or block templated seeding surfaces. Limited by the transient nature of oligomers making structural characterization difficult and accurate computational targeting challenging.",
"target_gene": "SNCA",
"composite_score": 0.55,
"evidence_for": [
{"claim": "Conformation-specific antibodies (ASyn295, NJ001) validate oligomers display unique surfaces", "pmid": "23643722"},
{"claim": "Oligomers exhibit distinct biological activities from monomers and fibrils", "pmid": "20167329"},
{"claim": "Toxic oligomer hypothesis supported by multiple cellular and animal models", "pmid": "21254973"}
],
"evidence_against": [
{"claim": "Transient oligomer nature makes structural characterization difficult for accurate computational targeting", "pmid": "25636995"},
{"claim": "Oligomer population heterogeneity complicates identification of druggable surfaces", "pmid": "28720782"}
]
},
{
"title": "Cryptic Pocket Stabilization to Prevent Conformational Conversion",
"description": "De novo design of minibinders (40–80 residue scaffolds) targeting cryptic allosteric pockets on monomeric αS that, when stabilized, trap the protein in a non-aggregation-competent conformation. Uses ensemble-based modeling or AlphaFold2-generated conformational states to identify pockets that shift the monomer ensemble away from β-sheet-prone states. Limited by computational challenges in designing for intrinsically disordered targets where pocket identification depends on sampled conformational states.",
"target_gene": "SNCA",
"composite_score": 0.45,
"evidence_for": [
{"claim": "EGCG remodels aggregates demonstrating ligand-induced conformational changes are possible", "pmid": "22365486"},
{"claim": "AlphaFold2 can generate conformational states for IDP pocket identification", "pmid": "34758328"},
{"claim": "Ensemble-based modeling approaches show promise for IDP targets", "pmid": "33424157"}
],
"evidence_against": [
{"claim": "αS monomers adopt heterogeneous conformations; pocket identification depends on sampled states", "pmid": "33424157"},
{"claim": "Designing for intrinsically disordered targets remains computationally challenging", "pmid": "34758328"},
{"claim": "Binding-induced conformational selection may not prevent aggregation if kinetics favor β-sheet formation", "pmid": "22365486"}
]
}
],
"synthesis_summary": "TheSynthesized ranking prioritizes H1 (NACore β-sheet interface targeting, score 0.65) as the most evidence-supported approach, reframed as a fibril elongation inhibitor rather than nucleation blocker based on Skeptic analysis demonstrating that cryo-EM structures represent end-states. H4 (aggregation competing sequences, score 0.62) ranks second with strong peptide-inhibitor precedent and improved scaffold design potential. H2 (oligomer-specific targeting, score 0.55) benefits from conformation-specific antibody validation but faces transient oligomer characterization challenges. H3 (cryptic pocket stabilization, score 0.45) remains most speculative due to computational IDP challenges. Key knowledge gaps include: primary vs. secondary nucleation distinction affecting all hypotheses, polymorphic fibril strain diversity requiring multi-target strategies, and validation pathway for BBB penetration in therapeutic development. Falsification experiments using seeded growth kinetics with substoichiometric seed ratios will differentiate fibril-end capping (H1, H4) from nucleation blocking mechanisms.",
"knowledge_edges": [
{"source_id": "H1", "source_type": "hypothesis", "target_id": "H4", "target_type": "hypothesis", "relation": "shares_fibril_end_targeting_strategy"},
{"source_id": "H2", "source_type": "hypothesis", "target_id": "H1", "target_type": "hypothesis", "relation": "oligomer_targeting_supplements_fibril_elongation_inhibition"},
{"source_id": "H3", "